Phase 0/I Study of AMG 232 Concentrations in Brain Tissue in Patients With Recurrent Glioblastoma and of AMG 232 in Combination With Radiation in Patients With Newly Diagnosed Glioblastoma and Unmethylated MGMT Promoters

Trial Profile

Phase 0/I Study of AMG 232 Concentrations in Brain Tissue in Patients With Recurrent Glioblastoma and of AMG 232 in Combination With Radiation in Patients With Newly Diagnosed Glioblastoma and Unmethylated MGMT Promoters

Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Oct 2017

At a glance

  • Drugs AMG 232 (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 13 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top